Shares are tanking today due to a missed goal in a mid-stage study. CNBC's Meg Tirrell reports. Also, home-grown Zika comes to the U.S. » Read More
CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene.
U.S. biotechnology company Celgene reported a 21 percent jump in quarterly revenue, driven by demand for its key multiple myeloma drug, Revlimid.
Alere is still is trying to close its multibillion-dollar purchase by Abbott Labs.
CNBC's Meg Tirrell reports on a promising new treatment for hemophilia by Biomarin. And Kadmon has a tough first day of trading.
Harlan Waksal, Kadmon CEO, discusses the company's IPO, and says the focus should be on the products in development going forward.
TauRx's drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer's, a study showed.
Andrew Witty, CEO of GlaxoSmithKline, explains why he was opposed to Brexit but adds that everything is now business as usual at the company.
Andrew Witty, CEO of GlaxoSmithKline, says the firm has been investing in bio electronic medicine for the last few years.
UK pharma giant records net loss for the second quarter but is set to gain from export-driven growth.
Andrew Witty, CEO of GlaxoSmithKline, comments on the company's earnings which beat expectations, with sales up 11 percent.
Eli Lilly on Monday announced that John Lechleiter, its chairman, president and CEO, will retire from the company effective December 31, 2016.
Eli Lilly reports better-than-expected quarterly sales, driven by demand for its newer treatments for diabetes and cancer.
Gilead Sciences lowered its full-year sales outlook, citing slower-than-expected demand for its hepatitis C drugs, and said profits fell 22 percent.
Analysts initiated shares of Allergan at an "outperform" rating, saying its diversified drug pipeline is underappreciated by investors.
Les Funtleyder, E Squared asset management, and Michael Yee, RBC biotech analyst, discuss trading health care and the future of biotech during the election.
Though the biotech sector has had a sharp turnaround since mid June, is the worst really over? The "Fast Time Halftime Report" traders discuss whether or not its worth buying the biotech bounce.
CNBC caught up with Biogen CEO George Scangos to discuss where he leaves the big biotech after six years at the helm.
Big drug discoveries have been scant, but investors can find long-term value in some biotech names, said Mark Schoenebaum of Evercore ISI.
Jean-Paul Clozel, CEO of Actelion, discusses the company's latest earnings results and discusses the pharma sector.
Human Longevity, Inc., will sequence your genome and identify how to fight the things that may shorten your life.
Get the best of CNBC in your inbox